首页> 外文期刊>中医科学杂志(英文) >Yiqi Yangyin and Huatan Quyu granule can improve skeletal muscle energy metabolism in a type 2 diabetic rat model by promoting the AMPK/SIRT/PGC-1α signalling pathway
【24h】

Yiqi Yangyin and Huatan Quyu granule can improve skeletal muscle energy metabolism in a type 2 diabetic rat model by promoting the AMPK/SIRT/PGC-1α signalling pathway

机译:益气养阴和化痰祛瘀颗粒可通过促进AMPK / SIRT /PGC-1α信号通路改善2型糖尿病大鼠骨骼肌能量代谢

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:To investigate how Yiqi Yangyin and Huatan Quyu granule (YYHO) improves skeletal muscle insulin resistance in a type 2 diabetic rat model and to discover whether the molecular mechanism is related to the promotion of the AMPK/SIRT/PGC-1α signalling pathway.Methods:Rats were randomly divided into 4 groups:the normal group,the model group,the YYHQ granule group,and the pioglitazone group.The type 2 diabetic rat model was established by feeding a high-fat diet for 5 weeks along with a single intraperitoneal injection of 30 mg/kg streptozotocin (STZ).After modelling successfully,the appropriate drug was intragastrically administered to diabetic rats for 2 weeks,once per day.The YYHQ granule group was given a dose of 4.8 g/kg body weight per day,the pioglitazone group was given a dose of 1.35 mg/kg body weight per day.The doses for both groups were equivalent to the clinical equivalent dose based on a previous study.Other groups were gavaged with the same amount of saline water.Body weight,food intake,water intake,urine volume and grip strength were recorded weekly.The fasting blood glucose(FBG) was determined weekly using blood glucose test strips.The related glucose and lipid metabolism indexes,e.g.,fasting insulin (Fins),glycated haemoglobin (GHb),HOMA-IR,ISI,triglycerides (TG),total cholesterol (TC),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C) and free fatty acid (FFA),were determined using biochemical method.The mRNA expression levels of adenosine monophosphate-activated protein kinase (AMPK),peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α),carnitine palmitoyl transterase-1 (CPT-1),Sirtuin 1 (SIRT1),and Sirtuin 3 (SIRT3) were assessed using quantitative real-time PCR (qRT-PCR).The protein expression levels of creatine kinase (CK),Ca2+ ATPase,α-Actin,AMPK,PGC-1α and CPT-1 were determined using enzyme-linked immunosorbent assay method (ELISA).Results:Body weight decreased significantly (P <.01),food intake,water intake and urine volume increased significantly (P <.01),and grip strength decreased significantly (P <.01) in the model group compared with the normal group.The levels of FBG,Fins,GHb and HOMA-IR increased significantly (P <.01),and the ISI decreased significantly (P <.01) in the model group.The levels of TG,TC,LDL-C and FFA increased significantly (P <.05 or P <.01),and the level of HDL-C decreased significantly (P <.05) in the model group.These changes were reversed after treatment with YYHQ granule or pioglitazone.Compared with the model group,the YYHQ granule and pioglitazone groups significantly improve body weight,water intake and urine volume (P <.05 or P <.01),however,both treatments had no significant effect on food intake (P >.05).The levels of FBG,Fins,GHb,HOMA-IR and ISI were improved significantly (P <.01) and the levels of TG,TC and LDL-C were improved significantly (P <.05 or P <.01),however,both treatments had no significant effect on the levels of HDL-C and FFA (P >.05).Further results indicated that YYHQ granule significantly decreased the mRNA expression of AMPK,PGC-1α,CPT-1,SIRT1 and SIRT3 in skeletal muscle (P <.01) and the pioglitazone group showed similar effects;moreover,the protein expression levels of CK,Ca2+ATPase,α-Actin,AMPK,PGC-1α and CPT-1 in skeletal muscle significantly decreased (P <.01),however,pioglitazone had no significant effect on CK and α-Actin (P >.05).Conclusion:The possible molecular mechanism of YYHQ granule improving skeletal muscle insulin resistance in a type 2 diabetic rat model may be related to the stimulation of energy metabolism in skeletal muscle via the AMPK/SIRT/PGC-1α signalling pathway.
机译:目的:探讨益气养阴和华坦祛瘀颗粒(YYHO)如何改善2型糖尿病大鼠模型的骨骼肌胰岛素抵抗,并探讨其分子机制是否与促进AMPK / SIRT /PGC-1α信号通路有关。方法:将大鼠随机分为4组:正常组,模型组,YYHQ颗粒组和吡格列酮组。采用高脂饮食5周并单次喂养建立2型糖尿病大鼠模型。腹膜内注射30 mg / kg链脲佐菌素(STZ)。成功建模后,每天两次向糖尿病大鼠胃内给药2周,每天一次。YYHQ颗粒组的剂量为每天4.8 g / kg体重,吡格列酮组的剂量为每天1.35 mg / kg体重。两组的剂量均等于先前研究的临床等效剂量。其他组均用相同量的盐水灌胃。每周记录体重,食物摄入量,水摄入量,尿量和抓地力。使用血糖试纸每周测定空腹血糖(FBG)。相关的糖脂代谢指标,例如空腹胰岛素(Fins),糖化血红蛋白(GHb),HOMA-IR,ISI,甘油三酸酯(TG),总胆固醇(TC),高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C)和游离脂肪酸(FFA)用生化方法测定。腺苷一磷酸激活蛋白激酶(AMPK),过氧化物酶体增殖物激活受体γ辅激活物-1α(PGC-1α),肉碱棕榈酰转移酶-1(CPT-1)的mRNA表达水平,使用定量实时荧光定量PCR(qRT-PCR)评估Sirtuin 1(SIRT1)和Sirtuin 3(SIRT3)。肌酸激酶(CK),Ca2 + ATPase,α-肌动蛋白,AMPK,PGC-1α和采用酶联免疫吸附法(ELISA)测定CPT-1。结果:体重显着下降与正常组相比,模型组的食物摄入量(P <.01),食物摄入量,水摄入量和尿量显着增加(P <.01),抓地力显着下降(P <.01)。模型组的Fins,GHb和HOMA-IR显着升高(P <.01),ISI显着降低(P <.01)。TG,TC,LDL-C和FFA水平显着升高(P <。)。 05或P <.01),模型组HDL-C水平显着降低(P <.05)。用YYHQ颗粒或吡格列酮治疗后,这些变化被逆转。与模型组相比,YYHQ颗粒和吡格列酮吡格列酮组可显着改善体重,摄水量和尿液量(P <.05或P <.01),但两种治疗对食物的摄入量均无显着影响(P> .05)。FBG,Fins和GHb的水平,HOMA-IR和ISI显着改善(P <.01),TG,TC和LDL-C水平显着改善(P <.05或P <.01)。征收结果显示,YYHQ颗粒显着降低了骨骼肌中AMPK,PGC-1α,CPT-1,SIRT1和SIRT3的mRNA表达(P <.01),且与正常人相比,差异有统计学意义(P <.01)。吡格列酮组具有相似的作用;此外,骨骼肌中CK,Ca2 + ATPase,α-肌动蛋白,AMPK,PGC-1α和CPT-1的蛋白表达水平显着降低(P <.01),但吡格列酮无明显意义。结论:YYHQ颗粒改善2型糖尿病大鼠骨骼肌胰岛素抵抗的分子机制可能与通过AMPK刺激骨骼肌能量代谢有关/ SIRT /PGC-1α信号通路。

著录项

  • 来源
    《中医科学杂志(英文)》 |2018年第002期|128-138|共11页
  • 作者单位

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

    School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号